Argentum and Alcon Settle Patent Dispute Over PAZEO®

NEW YORK, November 30, 2016 /PRNewswire/ — Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced today that it has reached a settlement with Alcon Research, Ltd., related to Argentum’s generic version of PAZEO® (0.7% olopatadine hydrochloride ophthalmic solution).

Under the terms of the settlement agreement, Alcon has granted Argentum a license to its U.S. patent covering PAZEO® for a generic version of PAZEO®. The agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering PAZEO®. The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.

PAZEO® is a registered trademark of Novartis AG Corporation.